Study on Bleximenib, Venetoclax, and Azacitidine for Treating Newly Diagnosed Acute Myeloid Leukemia (AML)

Inclusion Criteria

• Must be 18 years or older.
• Have newly diagnosed Acute Myeloid Leukemia (AML) with specific genetic changes (KMT2Ar or NPM1m) and at least 10% cancer cells in the bone marrow.
• Not eligible for intensive chemotherapy due to age (75 or older) or other health issues like heart, lung, kidney, or liver problems.
• Must have good liver and kidney function.
• Women must agree not to become pregnant or breastfeed during the study and for 6 months after the last treatment.
• Men must agree to use contraception during the study and for at least 90 days after the last treatment.
• Must be willing to sign a consent form to participate in the study.

Exclusion Criteria

• Have a type of leukemia called acute promyelocytic leukemia (APL).
• Have leukemia that has spread to the brain or spinal cord.
• Have had a solid organ transplant.
• Have serious heart problems like a recent heart attack or unstable chest pain.
• Have active hepatitis infection.
• Have received a live vaccine within 4 weeks before starting the study.
• Have known allergies to any of the study drugs.